TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

Colleen S. Sinclair; Camilo Adem; Ali Naderi; Cheryl L. Soderberg; Michele Johnson; Kangjian Wu; Linda Wadum; Vicki L. Couch; Thomas A. Sellers; Daniel Schaid; Jeffrey Slezak; Zach Fredericksen; James N. Ingle; Lynn Hartmann; Robert B. Jenkins; Fergus J. Couch

TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

Colleen S. Sinclair, Camilo Adem, Ali Naderi, Cheryl L. Soderberg, Michele Johnson, Kangjian Wu, Linda Wadum, Vicki L. Couch, Thomas A. Sellers, Daniel Schaid, Jeffrey Slezak, Zach Fredericksen, James N. Ingle, Lynn Hartmann, Robert B. Jenkins, Fergus J. Couch

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

Original language	English (US)
Pages (from-to)	3587-3591
Number of pages	5
Journal	Cancer research
Volume	62
Issue number	13
State	Published - Jul 1 2002

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{1e4f38a8058d472c8a3c394519db5223,

title = "TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors",

abstract = "The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.",

author = "Sinclair, {Colleen S.} and Camilo Adem and Ali Naderi and Soderberg, {Cheryl L.} and Michele Johnson and Kangjian Wu and Linda Wadum and Couch, {Vicki L.} and Sellers, {Thomas A.} and Daniel Schaid and Jeffrey Slezak and Zach Fredericksen and Ingle, {James N.} and Lynn Hartmann and Jenkins, {Robert B.} and Couch, {Fergus J.}",

year = "2002",

month = jul,

day = "1",

language = "English (US)",

volume = "62",

pages = "3587--3591",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

AU - Sinclair, Colleen S.

AU - Adem, Camilo

AU - Naderi, Ali

AU - Soderberg, Cheryl L.

AU - Johnson, Michele

AU - Wu, Kangjian

AU - Wadum, Linda

AU - Couch, Vicki L.

AU - Sellers, Thomas A.

AU - Schaid, Daniel

AU - Slezak, Jeffrey

AU - Fredericksen, Zach

AU - Ingle, James N.

AU - Hartmann, Lynn

AU - Jenkins, Robert B.

AU - Couch, Fergus J.

PY - 2002/7/1

Y1 - 2002/7/1

N2 - The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

AB - The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRC1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036645397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036645397&partnerID=8YFLogxK

M3 - Article

C2 - 12097257

AN - SCOPUS:0036645397

SN - 0008-5472

VL - 62

SP - 3587

EP - 3591

JO - Cancer research

JF - Cancer research

IS - 13

ER -

TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this